Skip to main content
Micromachines logoLink to Micromachines
. 2022 Jun 20;13(6):978. doi: 10.3390/mi13060978

Rational Design of Microfluidic Glaucoma Stent

Thomas Graf 1, Gitanas Kancerevycius 2, Linas Jonušauskas 2, Patric Eberle 1,*
Editor: Ottavia Jedrkiewicz
PMCID: PMC9229318  PMID: 35744591

Abstract

Glaucoma is a common, irreparable eye disease associated with high intraocular pressure. One treatment option is implantation of a stent to lower the intraocular pressure. A systematic approach to develop a microchannel stent meshwork that drains aqueous humor from the anterior chamber of the eye into the subconjunctival space is presented. The stent has a large number of outlets within its mesh structure that open into the subconjunctiva. The development approach includes a flow resistance model of the stent. Local adaption of the stent’s tubular dimensions allows for adjustment of the flow resistance. In this way, an evenly distributed outflow into the subconjunctiva is achieved. We anticipate that microblebs will form at the stent outlets. Their size is crucial for drainage and control of intraocular pressure. An analytical model for bleb drainage is developed based on the porous properties of the subconjunctival tissue. Both models—the stent flow resistance model and the bleb drainage model—are verified by numerical simulation. The models and numerical simulation are used to predict intraocular pressure after surgery. They allow for a systematic and personalized design of microchannel stents. Stents designed in this way can stabilize the intraocular pressure between an upper and lower limit.

Keywords: microfluidic stent, glaucoma, flow resistance model, bleb drainage, IOP stabilization

1. Introduction

Glaucoma is the leading cause of irreversible blindness and causes high healthcare costs as well as impaired quality of life and suffering for those affected [1,2,3]. It is estimated to affect more than 60 million people worldwide, with incidence increasing with age, and is most prevalent in Africa and Asia [1,2,3]. Glaucoma belongs to a group of neurodegenerative eye diseases in which the optic nerve and retinal ganglion cells are damaged, caused by elevated intraocular pressure (IOP) [1]. Therapy aims to reduce IOP and may include medication, laser trabeculoplasty or surgery for the treatment of primary open angle glaucoma (POAG), ocular hypertension (OHT) and normal tension glaucoma patients (NTG) [4,5].

Non-invasive treatments with medications and laser trabeculoplasty may not be sufficiently effective or may be associated with side effects in some patients [4]. Patients with IOP that poses a significant risk for progressive glaucoma damage leading to visual impairment, where non-invasive treatments were not successful, are candidates for surgery [5]. In standard trabeculectomy surgery, the outflow resistance of the aqueous humor (AH) is reduced by opening a channel from the anterior chamber through the sclera into the subconjunctival space [6]. The draining AH forms a bleb in the subconjunctival space. From the bleb, AH drains into the subconjunctiva and is absorbed by the highly vascular tissue. However, the outflow facility may decrease postoperatively due to fibrotic reactions and scarring in the subconjunctiva [4,6,7,8]. Alternatively, a glaucoma drainage device (GDD) can be implanted to assist and control the drainage of AH from the anterior chamber through an artificial tube connection [4,9,10,11,12]. Several GDDs have been developed that drain AH into the subconjunctival space (Xen, Allergan Inc., Dublin, Ireland; ExPress, Alcon Inc., Geneva, Switzerland), Schemm’s canal (iStent inject, Glaukos Inc., San Clemente, CA, USA; Hydrus, Alcon Inc., Geneva, Switzerland), suprachoroidal space (CyPass, Alcon Inc., Geneva, Switzerland; Solx Gold Shunt, SOLX Inc., Waltham, MA, USA) or outside (Ahmed glaucoma valve plate AGV PF7, New World Medical Inc., Rancho Cucamonga, CA, USA) [4,5]. Solx Gold Shunt is a microfluidic device that distributes AH into the suprachoroidal space through multiple outlets. However, GDD implantation can also lead to fibrotic reactions and scarring postoperatively, resulting in an increase in IOP again after an initial decrease in IOP [4,13]. In subconjunctival drainage, the morphology of the bleb is critical to its drainage capability into the tissue, and the morphology of the bleb may change after surgery resulting in IOP variations, which has been repeatedly studied for both standard trabeculectomy and GDD implants [14,15,16,17].

Stable AH outflow is critical for IOP lowering and stabilization, which can be impaired by scarring and bleb changes. The aim of this study was to investigate and optimize the fluidic properties of a microfluidic stent meshwork that reduces the risk of fibrosis development by its design and that drains into the subconjunctival space with multiple microblebs for IOP stabilization. A fluidic model was developed, including microbleb and tissue behavior enabling step-by-step personalized design of the microfluidic stent.

It has been shown that the appropriate choice of materials as well as the architecture of the GDDs can affect and reduce the postoperative development of fibrosis and scar formation [13,18,19]. A flexible microfluidic stent meshwork implanted in the subconjunctival space with channel sizes of cellular dimensions has demonstrated significantly less fibrosis development than the AGV PF7 in animal models [18]. Although the basic mechanisms for fibrotic response and capsule formation around glaucoma drainage devices are not clearly understood, Amoozgar et al. suggested that two implant-specific factors give rise to tissue reactions: (1) mechanical stress may develop at the interface between the tissue and the implant (e.g., due to a mismatch of mechanical properties) and (2) the implant disrupts the cellular and vascular system of the tissue [18]. It is hypothesized that the incorporation of these two key features into the design of the microfluidic network reduces the development of fibrotic tissue around the implant.

Figure 1 schematically shows the placement of the studied microfluidic stent in the eye that drains AH into the subconjunctival space. Part A of the stent collects AH in the anterior chamber of the eye and drains it via part B into part C, a microfluidic mesh. Part C is inserted in the subconjunctiva, on the scleral barrier. The bypass drainage through the stent serves to lower and regulate IOP. It is very important to also include drainage into the subconjunctival tissue and the associated pressure at the stent outlets in the analysis. The outflow of AH into the tissue leads to bleb formation. We argue that microblebs form at each stent outlet, as indicated in Figure 1b. The outflow is uniformly distributed over an area of 0.65 cm2 using multiple outlets in the hexagonal meshwork of the current stent design, as shown in Figure 2. The cell-sized dimensions of the microchannels are expected to reduce the risk of fibrosis [18]. IOP can be adjusted by varying the dimensions of the outlet tubes of the stent, while the mesh structure and the dimensions of the mesh channels remain fixed. Large cross-sections are adopted for part A and part B to achieve a near-zero pressure drop until the distribution of AH in Part C. For the meshwork of part C in Figure 2, we used a honeycomb structure with thin connections (channels). The hexagonal geometry provides high in-plane stability and high flexibility for out-of-plane deformations [20]. This preserves the channel dimensions and the uniform outflow of AH into the subconjunctiva, while allowing the mesh to conform to the tissue in the out-of-plane direction at low mechanical stress. In the remainder of the paper, we will discuss only Part C of the stent, which we will refer to simply as the stent or meshwork.

Figure 1.

Figure 1

(a) Sectional anatomy of the eye with glaucoma stent. Part A is placed in the anterior chamber to collect AH. Part B conducts the AH into the meshwork of part C. Part C drains the fluid into the subconjunctival tissue. (b) Drainage pathways and flow balance in the eye after surgery. AH is produced in the ciliary body and drained by the trabecular meshwork (TM) via Schlemm’s Canal, the uveoscleral pathway (UP) and the stent. At the stent outlets, blebs form in the subconjunctiva on the scleral barrier. The indicated flow rates were used in numerical simulation.

Figure 2.

Figure 2

The meshwork consists of honeycomb cells and is 12.6 mm wide and 5.2 mm high. Each hexagonal segment is a microtube (microchannel) with a square internal cross-section 14 μm wide. Each honeycomb cell contains an outlet tube with specific dimensions and a corresponding flow resistance (see enlarged detail). The black numbers are the dimensions; the red numbers denote the columns and rows of the meshwork. The liquid flows evenly from part B above into the meshwork.

The paper is organized as follows. In Section two, the methods of numerical simulation are briefly explained. Section three describes the models developed to calculate the pressure drop in the stent, including the absorption of the liquid in the subconjunctival tissue. The section concludes with the calculation of IOP after surgery (IOPAS) using the current stent design. Section four concludes the present work.

2. Numerical Methods

The computational microfluidics of the stent’s tubular mesh (Figure 2) were performed with the software COMSOL Multiphysics 5.6® [21] employing the finite element method (FEM). We used the Laminar Flow interface of the Fluid Flow module and the physical model Creeping Flow. The outflow from the stent openings into the subconjunctival tissue was calculated by means of the Darcy’s Law interface of the Porous Media and Subsurface Flow branch in COMSOL. Finite element meshes were generated automatically using the COMSOL option Physics Controlled Mesh. Typical element size was Finer. COMSOL and the Electrical Circuit interface of the AC/DC module were used to verify the resistor network. We always computed stationary solutions.

3. Mathematical Models

An equivalent model with lumped fluidic resistances was developed to calculate the pressure drop across the stent. The resistors were determined from the stent geometry. The model was validated using COMSOL simulations. After that, the role of blebs at the stent outlets was investigated. Drainage of fluid from the bleb into the surrounding subconjunctival tissue was modeled using Darcy’s law for porous media [6]. This was calculated analytically and confirmed by COMSOL simulation. IOPAS is a function of three drainage pathways, including the pressure in the blebs and the pressure drop across the meshwork. The natural outflow via TM, which is typically insufficient in open-angle glaucoma patients, as well as the uveoscleral outflow, were considered in the prediction of the IOPAS. They can be treated as parallel flow to the stent outflow [9,22].

3.1. Circuit Model of Stent Flow

Exploiting the symmetries of the hexagonal mesh, the equivalent circuit with lumped-resistances of the flow path along a column (in the negative y-direction) can be derived, see Figure 3. The flow resistance R of a straight hexagon segment can be calculated with the channel dimensions following Hagen–Poiseuille’s law [23]. For a channel with a square cross-section, the equation for the flow resistance is [24]:

R28.4·ηLD4  , (1)

where L is the segment length, D is the cross-sectional width of the channel and η7×104 Pa·s is the dynamic viscosity of the humorous fluid (saline water at 37 °C). The base element of the lumped resistor model, R0 connecting two outlet tubes of consecutive rows, can be modeled by a star connection (see Figure 3c) whose contact resistance is R0=32R (for details see Appendix A). The contact resistance therefore is

R0=42.7·ηLD4  . (2)

Figure 3.

Figure 3

Tubular structure of the stent and fluid resistance model. (a) The honeycomb meshwork geometry is the same everywhere; only the outlet tubes have different dimensions. The star-shaped part, colored in red, can be expressed as a fluidic resistance R0 between two subsequent outlet tubes. (b) Equivalent circuit diagram of a single column of the stent, from the fluid inlet (top) to the individual outlets. The numbered resistors R1 to R20 correspond to the various outlet tubes along the stent column. Due to the different dimensions, the outlet tubes have distinct flow resistances. The dimensions are chosen so that the same rate of liquid flows out of each tube. The diagram in (c) illustrates how the resistance R0 can be calculated using the flow resistance R of a straight channel segment (marked in blue). Drawing (d) depicts the relevant geometric entities for the calculation of the flow resistance.

For the squared outlet tube, the flow resistance Rk at row k is calculated as in Equation (1):

Rk28.4·ηLkDk4  , (3)

where Lk is the tube length and Dk is the cross-sectional width of the outlet tube, as shown in Figure 3d. The sequence of connecting resistors R0 and outlet resistors Rk is the equivalent circuit of the flow path along a column in the mesh (in the negative y-direction) shown in Figure 3b. COMSOL simulations showed that boundary corrections in the first and the last column (out of 42 columns) of the network can be omitted without loss of accuracy. To obtain the same outflow Q˙t from each outlet tube, the flow rate to row k1  must be k1Q˙t. This can be ensured if the resistance Rk of each outlet tube is k1Rrestk1, where Rrestk1 is the flow resistance of the circuit below row k. Rk can thus be expressed in terms of R0 and R1. Examples of R1 to R5 are given in Table 1. The general equation of the outlet tube resistance in row k is

Rk=k1Rrestk1=12kk1R0+R1  . (4)

Table 1.

Equations to calculate the outlet tube resistances as a function of the connecting resistance R0 and the bottom outlet resistance R1. Only the equations for the lowest outlet tubes are shown in the table. The general equation for the outlet resistance of row k is presented in the text (Equation (4)). Rrestk1 is the flow resistance of the circuit below row k.

Row k Resistance of Outlet Tube in Row k Resistance of Circuit Below Row k
1 R1
2 R2=Rrest1=R0+R1 Rrest1=R0+R1
3 R3=2Rrest2=2R0+R2Rrest1R2+Rrest1=2R0+12Rrest1=3R0+R1 Rrest2=32R0+12R1
4 R4=3Rrest3=3R0+R3Rrest2R3+Rrest2=3R0+23Rrest2=6R0+R1 Rrest3=63R0+13R1
5 R5=4Rrest4=4R0+R4Rrest3R4+Rrest3=4R0+34Rrest3=10R0+R1 Rrest4=104R0+14R1

The total resistance of a honeycomb stent column (compare to Figure 3a,b) is thus

Rc=R2+RnrRrestnr1Rnr+Rrestnr1=R03+RnrRnrnr1Rnr+Rnrnr1=nr216R0+R1nr  , (5)

where nr is the number of honeycomb rows. The term R/2 on the left of Equation (5) stems from the short, straight channel segment between stent part B and the first outlet (see Figure 3). The correctness of Equation (5) has been verified with a simulation using the Circuit Interface of the AC/DC module of COMSOL Multiphysics 5.6® [21]. The lowest resistor R1 contributes little to the total resistance and is a free design parameter. It shall be noted that the channels below the lowest outlet tube in row 1 (below resistance R1) are preferably closed to avoid stagnant liquid.

AH production rate varies among individuals and was found to slightly decrease with age and to be relatively independent of IOP (see Appendix B for details, also regarding POAG/OHT patients). In the 20- to 83-year age group, it was reported as 2.4±0.6 μL/min (mean ± SD) during daytime, with diurnal variations: morning 3.0 μL/min, afternoon 2.4 μL/min and night 1.5 μL/min [25]. We set the production rate to Q˙=2.5 μL/min and then accounted for the diurnal variation of the rate in the analysis of IOPAS. The presented model for designing stents can be easily personalized to other production rates by setting Q˙ in the step-by-step procedure presented in Appendix C. Part of the AH is drained via TM and the other part via UP [6,26]. Reported fractions of uveoscleral outflow vary between 4 and 54% and depend not only on biological factors but also on the measurement method (see Appendix B for details) [25,27]. We set uveoscleral outflow Q˙up at 15% of total outflow (Q˙up=0.15·Q˙=0.4μLmin). The flow rate through the stent Q˙s ranges from 1.5 to 1.8μL/min. It depends on the fluid resistance of TM and on IOP, as explained in Section 3.4 and Appendix C. In the following computations we used a typical Q˙s=1.7 μL/min. For the stent shown in Figure 2, the values in Table 2 were obtained. The dimensions of the stent meshwork and of the lowest outlet tube (resistance R1) were chosen to reach IOPAS=14 mmHg (see Section 3.4). The latter is a free design parameter of the stent and is selected within a healthy range. It is important to understand that the dimensions of the channel cross-sections must be maintained very precisely in order to achieve the targeted resistance value of the stent (or the targeted IOPAS). Equations (1) and (2) show that the cross-sectional width of the tube enters with the fourth power. Small dimensional variations have a large effect. Consequently, the manufacturing process of the stent must be of high precision and reproducibility.

Table 2.

Resistances, flow rates and pressures of the meshwork of Figure 1 and Figure 2. The resistances R and R1 are obtained from the channel geometry. The stent flow rate Q˙s is an example value after surgery. The pressure difference ps across the stent is then calculated with the stent fluid model using the mentioned quantities or with COMSOL simulations using the specified geometry.

R 9.0×1013
11.2
Pa·s/m3
mmHg·min/μL
Equation (1) D×D×L=14 μm×14 μm×173 μm
R0 1.35×1014
16.8
Pa·s/m3
mmHg·min/μL
Equation (2)
R1 1.35×1013
1.69
Pa·s/m3
mmHg·min/μL
Equation (3) D1×D1×L1=14 μm×14 μm×26 μm
 Rc 1.33×1015
166
Pa·s/m3
mmHg·min/μL
Equation (5) Resistance of a whole column composed of 20 rows
Rs 1.16×1013
3.95
Pa·s/m3
mmHg·min/μL
Rc42 Resistance of a whole stent meshwork composed of 20 rows and 42 columns
Q˙s 1.7 μLmin specified typical stent flow rate
Q˙c 40 nLmin =Q˙s/42 Flow rate of a whole column of 20 outlet tubes
Q˙t 2.0 nLmin =Q˙s/42×20 Flow rate of a single outlet tube
psmodel 6.7 mmHg =Rc·Q˙c=Rs·Q˙s
psCOMSOL 6.3 mmHg COMSOL simulations Section 3.2. and Figure 4

3.2. Numerical Model of Stent Flow

The lumped resistance model was validated by computational fluid dynamics with the software COMSOL Multiphysics® [21]. Since the flow in the stent meshwork is in the low Reynolds regime Re1, it is a so-called Stokes flow for which the physical model Creeping Flow from COMSOL can be used. This physics omits the inertial term in the Navier Stokes equation: ϱu·u=0, where ϱ is the fluid density, u the fluid velocity and the Nabla operator. Tests with the fully laminar formulation did not show any differences. Computation time in this case was, however, 30% longer.

The last two rows of Table 2 show that the circuit calculation of the pressure across the stent using the lumped resistor model agrees to within 5% with the COMSOL simulation. Furthermore, numerical simulation showed that the outflow at each stent opening is Q˙t=2.0±0.4nLmin consistent with Q˙s divided by the number of stent outlets. The lowest outlet row, however, gives a slightly higher outflow, independent of the mesh refinement. This is a consequence of the unfavorable length-to-diameter ratio of the lowest outlet tubes where Hagen–Poiseuille’s law for long narrow tubes no longer applies. Furthermore, the remaining flow rate in the lowest tubes is very small and numerical uncertainty increases. Other, small variations in outflow are random and due to numerical inaccuracies. Smaller FEM mesh sizes result in similar flow variations at the individual openings and can be considered “numerical noise”. The integral of the velocity field across all orifices yields a total outflow of 1.7μLmin. This is equal to the total inflow, which is a boundary condition and demonstrates consistency. Figure 4 shows the pressure drop across the stent mesh and the velocity field in the midplane of the stent channels. The highest velocity of 7mms occurs in the center of the channels at the inlet to the meshwork. The velocity in the center of the lowest channel is 0.3 mm/s. In summary, the numerical flow simulation confirmed our lumped resistance model with high accuracy.

Figure 4.

Figure 4

Pressure and flow velocity field in the microchannel mesh computed with the program COMSOL. The boundary conditions were the inlet flow rate of 1.7μLmin and the outlet pressure of 0 mmHg at each orifice. (a) Pressure distribution in the stent of the leftmost and rightmost part of the mesh. The maximum value is 6.3 mmHg at the inlet, above row 20. (b) Flow velocities in the midplane of the meshwork. Shown are flow details at top and bottom of the stent, along the centerline of the honeycomb structure.

3.3. Model of Drainage to Subconjunctival Tissue

The AH drains from the stent into the surrounding, highly vascular subconjunctival tissue. Blebs form in the subconjunctival space at the outlets of the stent [4]. The pressure at the outlets is also the pressure in the bleb and is determined by the absorption properties of the porous subconjunctival tissue around the bleb, and the size and shape of the bleb. The microscopic capillaries in the subconjunctiva with their complex ramification and varying sizes can be transferred into a homogeneous model using Darcy’s law that emulates the complex microvascular structure [6]. We used COMSOL Multiphysics® to compute Darcy’s law inside the tissue. The FEM program solves the following equation for the pressure p:

ϱκηΔpSpp=0  , (6)

where Δ is the Laplace operator, ϱ is the density of the fluid, κ is the fluid permeability in the subconjunctival tissue and η is the dynamic viscosity of the fluid (saline water). The ratio K=κη is referred to as hydraulic conductivity [6]. Spp corresponds to the source term in Darcy’s law for fluid removal through or fluid entry into the blood capillaries in the tissue. The constant Sp can be expressed as Sp=ϱ·LpSAV, where Lp and SAV are the hydraulic permeability of the blood vessel walls and the surface area of the vessel walls per tissue volume, respectively [6].

The pressure p of the source term in Equation (6) is composed of the hydrostatic and oncotic pressure differences between capillaries and interstitium. It can be derived from Starling’s law as p=pcpi σπc πi, where pc,i are the hydrostatic and πc,i the oncotic capillary and interstitium pressures and σ is the reflection coefficient [6,28]. For our numerical simulations and analytical models, we used the generally accepted subconjunctival properties given in Appendix D. For normal tissue, pcσπc πi0, yielding p=pi, which is the dependent variable solved for [6,29].

The meshwork is implanted between the subconjunctiva and the sclera during the operation. The subconjunctival tissue closes onto the surface of the meshwork during healing. An initial bleb with the extension of the meshwork or larger is likely to form, with low drainage resistance and low bleb pressure during the early postoperative phase [4]. As healing continues, the subconjunctiva closes onto the individual outlets of the stent. Microblebs form. This presumably completes the healing process. An analytical model of drainage of a single microbleb within absorbent tissue is developed and numerically validated in Section 3.3.1. A simulation of a microbleb array in the subconjunctiva is presented in Section 3.3.2.

3.3.1. Drainage from Hemispherical Microbleb

Microblebs presumably form around each outlet orifice of the stent in the course of healing. We assume hemispherical microblebs, although morphological observations of macroblebs have revealed different, non-spherical shapes [15,16,17]. We justify our assumption by the following facts: (i) The stent is resting between the subconjunctival tissue and the scleral barrier, which is assumed impermeable. Hydraulic conductivity of the sclera is significantly smaller than that of the subconjunctival tissue ( by a factor 50), thus the sclera is modeled as impermeable. (ii) The stent has multiple outlets with sufficient separation between them and the flow rate per outlet is very small, Q˙t=2.0nLmin (see Table 2). (iii) The fine stent structure facilitates tissue overgrowth and causes only little disruptions in the tissue structure, which has been shown to reduce the risk of fibrosis and scar development [18]. Low fibrosis and little scarring has the advantage that the fluid permeability of the tissue stays high and does not change over time. Drainage remains predictable and more stable. A healthy subconjunctival tissue ensures long-term stability of IOP in the operated eye. For the reasons (i) to (iii), hemispherical microblebs are likely to form around each outlet orifice.

In the following, we calculate the pressure in a hemispherical bleb due to the drainage resistance in the subconjunctival tissue. In spherical coordinates and exploiting spherical symmetry, the governing Equation (6) becomes

1r2ddrr2ddrpSpϱηκp=0  , (7)

whereby the angle dependence disappears: ddϕ=ddθ=0. The r is the distance from the coordinate origin. Equation (7) can be rewritten as rd2dr2p+2ddrpSpϱηκrp=0. With the substitution q=r·p this equation becomes d2dr2qSpϱηκq=0 from which follows the solution of Equation (7) as

pr=BreC·r ,  (8)

where C=Spϱηκ=2.0×1061m2 (see above) and B is a constant to be determined from the flow rate Q˙t of the outlet tube into the bleb. The quantity 1/C=0.7 mm can be considered as the characteristic drainage length. Equation (8) satisfies the boundary condition that the fluid pressure is zero far from the bleb: p=0. Darcy’s law and spherical symmetry provide the equation for the radial flow velocity ur inside the vascular tissue:

ur=κηrpur=κηBCr+1r2eC·r  , (9)

where r=ddr is the gradient operator in radial direction. From the bleb, the flow Q˙b drains into the surrounding tissue and is absorbed there. Q˙b is equal to Q˙t in the outlet tube of the stent. Q˙b relates to the velocity ub at the hemispherical surface of the bleb of the radius rb in the following way:

ub=Q˙b2π rb2  . (10)

Note the factor of 2 instead of 4 in Equation (10), which accounts for drainage through half of a spherical shell. The hemispherical bleb is assumed to rest on the impermeable scleral barrier and there is no drainage in that direction. Combining Equations (9) and (10) in ub=urrb yields the constant B:

B=ubηκ1Crb+1rb2eC·rb=Q˙b2πηκ1rbC+1eC·rb  . (11)

Equation (11) inserted into Equation (8) yields the pressure at the bleb surface, that is, where the fluid enters the vascular subconjunctival tissue:

prb=pb=Q˙b2πηκ1rb2C+rb  . (12)

Equations (8)–(12) were verified by means of COMSOL computations. Figure 5 shows the pressure obtained by numerical simulation in the subconjunctival tissue outside a bleb with radius rb=30 μm. In Figure 5b, the numerical result is compared to the analytical solution of Equation (8). The figure shows that both methods of calculating pressure as a function of distance from the origin are in exact agreement.

Figure 5.

Figure 5

(a) COMSOL simulation of the outflow from a bleb with radius rb=30 μm. The inlet boundary condition is the mass flow rate M˙=Q˙b·ϱ=3.3×1011kgs at the hemispherical bleb surface. This corresponds to Q˙b=Q˙t=2.0nLmin, given in Table 2. The outer boundary condition is the pressure pd=0.17 mm Hg at the domain boundary at rd=300 μm. pd is calculated by means of Equations (8) and (11) and used to mimic an infinite domain. The white lines and arrows indicate the flow direction given by the simulation. The axis of rotational symmetry is shown as a vertical, dashed red line. (b) Pressure as a function of distance from the origin. The blue line is the COMSOL result; the red circles are obtained using Equations (8) and (11).

If all stent outlet tubes empty into a hemispherical bleb the stent pressure increases by the pressure of Equation (12). In other words, the flow resistance Rb of the bleb drainage must be added to each outflow resistance of the stent. The drainage resistance from the bleb to the tissue is calculated as follows:

Rb=pbQ˙b=η2π κ·1rbrbC+1η2π κ rb  . (13)

The last term of Equation (13) is an approximation that applies with an accuracy of 10% for bleb radii rb<70 μm, i.e., rbC<0.1. The drainage resistance is inversely proportional to the radius of the bleb. If the bleb shrinks and its radius reduces to the radius of the outlet tube (10 μm), the bleb drainage resistance becomes Rb4 mmHg·min/nL.

A hemispherical perforated shell can be produced at each outlet as part of the stent. This would define the minimum size of the bleb and limit the maximum drainage resistance. Thus, the upper IOP limit can be set by the stent design.

3.3.2. Drainage from Bleb Array

The hexagonal structure of the present stent meshwork results in the hexagonal array of 42×20 blebs depicted in Figure 6a. The bleb array is situated on the scleral barrier, below the 0.6 mm thick subconjunctiva. The hemispherical bleb surfaces empty AH into the adjacent subconjunctival tissue. Equation (13) of the bleb drainage resistance applies to a single bleb embedded in extended absorbent tissue. The proximity of other blebs in the array of Figure 6 and the limited thickness of the subconjunctiva increase the drainage resistance of the blebs. Equation (13) must be considered as the lowest possible bleb drainage resistance. We used Darcy’s law (Equation (6)) and the characteristic tissue values given in Appendix D to calculate the drainage resistance of a bleb array. Figure 6b,c shows the pressure in the subconjunctival tissue obtained by COMSOL simulation. All hemispherical blebs in the hexagonal arrangement of Figure 6 have a radius rb=30 μm and are separated from each other by da=300 μm. The constant pressure at the bleb surfaces divided by the flow rate of AH through the stent and the bleb surfaces yields the array drainage resistance. Drainage resistance is independent of the flow rate (Equation (6) is a linear partial differential equation). The array drainage resistance Ra is used to calculate IOPAS in Section 3.4.

Figure 6.

Figure 6

(a) Microbleb array of 12.6×5.2 mm2 of the current stent meshwork. The microblebs lie on the scleral barrier and are spaced 300 µm apart. All blebs have a radius of rb=30 μm. AH flows from the bleb surfaces into the 0.6 mm thick subconjunctiva. (b,c) Drainage pressure field in the subconjunctival tissue determined by COMSOL simulation. The total flow rate of the bleb array is 1.7μLmin. Figure 6b shows a quarter of the simulation domain. Figure 6c is an enlarged view of 6b. The pressure inside the blebs is 7 mmHg and reaches 4.1 mmHg at the surface of the subconjunctiva. The pressure decreases rapidly in the plane of the array within the characteristic length 1/C=0.7 mm.

Figure 7a shows the array resistance Ra as a function of bleb separation distance da. All bleb radii are equal to rb=30 μm in Figure 7a. At large separation drainage resistance of the array approaches the resistance of an isolated bleb according to Equation (13), divided by the number of blebs in the array: Rada=Rbrb=30μm42·20=1.5 mmHgminμL. The horizontal line in Figure 7a indicates this lower limit.

Figure 7.

Figure 7

Drainage resistance Ra obtained by COMSOL simulations of hexagonal arrays as in Figure 6. (a) Ra as a function of bleb spacing da. The bleb radius is constant rb=30 μm. The curve reaches the value of 1.5 mmHgminμL for large separations, which is consistent with Equation (13) for free blebs. (b) Ra  as a function of bleb radius rb. The bleb spacing is constant at da=300 μm. For bleb radii rb>30 μm, the curve terminates in a constant value corresponding to the drainage resistance of a shallow macrobleb of 12.6×5.2 mm2 surface area.

Figure 7b shows Ra as a function of bleb radius rb at constant bleb spacing da=300 μm. The array drainage resistance approximates the value of a single, shallow macrobleb covering the entire stent outlet area of 12.6×5.2 mm2 when the blebs overlap completely. Figure 7b demonstrates that for bleb radii larger than 30 μm the array drainage resistance is almost constant between 4 and 3 mmHg·min/μL. This allows the IOP to be set relatively precisely, regardless of the bleb diameter, as long as it does not fall below a minimum size. The minimum diameter can be integrated in the stent design, as explained at the end of Section 3.3.1.

3.4. IOP after Surgery

By combining the equations and findings above, the effectiveness of the stent in lowering IOPAS can be analyzed. In a first step, the flow resistance of TM RTM of the diseased eye is determined using the Goldmann equation:

Q˙=IOPBSpEVRTM+Q˙UP  , (14)

where IOPBS is the IOP before surgery and pEV=11 mmHg is the episcleral vein pressure. The resistance RTM can be determined by solving Equation (14) using the known IOPBS. In the second step, IOPAS is calculated by extending the Goldmann Equation (14) with the additional term Q˙S=IOPASRsa· for the stent flow rate:

Q˙=IOPASpEVRTM+IOPASRsa+Q˙UP (15)
IOPAS=Q˙Q˙UP+pEVRTM1RTM+1Rsa=Q˙Q˙UP·Rsa·IOPBSQ˙Q˙UP·Rsa+IOPBSpEV  , (16)

where Rsa is the total flow resistance from stent entry to drainage in the tissue. Rsa=Rs+Ra is the series resistance of the stent resistance Rs=Rc/42 (see Table 2) and the bleb array resistance Ra (see Figure 7). The current stent consists of 42 columns and 20 rows. Equation (16) assumes that pEV is the same in the diseased and healthy eye. Figure 8 shows IOPAS as a function of bleb radius, calculated with Equation (16) for various IOPBS. For bleb radii larger than 30 μm the postoperative IOPAS is between 12 and 15 mmHg for preoperative IOPBS ranging from 20 to 35 mmHg. A bleb size of r=30 μm presumably disrupts the surrounding tissue little [18]. The microbleb size is then of the order of a few cell diameters. This implies that fibrosis is unlikely and scars are also unlikely to form. This in turn means that the subconjunctival absorption properties remain unchanged and drainage into the tissue does not alter. Consequently, IOPAS should remain constant over time. The higher limit of bleb size is given by the distance between them and possible overlaps, but also by the available space in the subconjunctiva. In case the microblebs overlap and form a larger macrobleb, the pressure in the bleb could become nearly zero. The lower IOP limit can be adjusted in this case by the pressure drop across the stent to prevent hypotony.

Figure 8.

Figure 8

IOPAS as a function of microbleb radius rb. The bleb separation is da=300 μm corresponding to the geometric period in the current honeycomb design. The numbers in the boxes are the IOP values before surgery in units of mmHg. The curves were calculated using Equation (16) and Q˙. IOPAS ranges from 12 and 15 mmHg for bleb radii greater than 30 μm. The green shaded area corresponds to the IOPAS for AH production rate varying between 1.5 and 3.0 μL/min and an IOP before surgery of 25 mmHg. The green shaded area demonstrates that the IOP is within a healthy range even with daily fluctuating production rates [4].

3.5. Study Limitations

The model presented in this study has the following limitations. Published and accepted values were used for the properties of the subconjunctival tissue. They are associated with uncertainties or may change postoperatively due to wound healing and/or medication [6,14]. The trabecular flow resistance RTM was treated as constant in the model, i.e., as a linear flow-pressure relation through TM. RTM may increase at higher IOP, partly due to the collapse of Schlemm’s canal [9]. However, studies have shown that clinical observations can be reproduced with the aforementioned limitations of the model [6,22]. Finally, the meshwork-based stent under investigation, including the presumed formation of microblebs, has not been tested in vitro or in vivo.

4. Conclusions

The proposed stent can effectively lower elevated IOP to a level in the target range between 10 and 15 mmHg [4]. Outflowing AH is uniformly distributed over an area of 0.65 cm2 into the subconjunctival tissue via multiple microblebs. We find that IOP is almost insensitive to microbleb size variations (ΔIOPAS  1 mmHg for 30 μmrb150 μm). Lower and upper IOP can be limited with the stent design. The lower limit is determined by the stent resistance if the bleb is large. The upper limit can be set with a perforated shell at each stent outlet, defining the minimum bleb size. The computational models presented can predict IOP after stent implantation. The models enable a step-by-step procedure for a personalized stent production (see Appendix C).

A prerequisite for personalized production is a reproducible and high-precision manufacturing process. The femtosecond laser-induced 2-photon photopolymerization (2PP) technology meets these conditions and guarantees the necessary precision. It combines printing resolution down to hundreds of nm with throughput rivaling micro stereolithography (µSLE) at sub-mm and mm scales [30]. It allows using various biocompatible polymers, assuring superb biocompatibility and adequate mechanical properties needed for medical applications [31,32].

It should be mentioned that the outlet resistances from the hexagonal stent meshwork can also be realized in ways other than straight, narrow and perpendicular outlet tubes. For example, the tubes could be adhered to the main channels. Or a thicker outlet tube with internal resistance could be fabricated. Or a meandering design could be chosen.

In vitro or in vivo study of the presented microfluidic meshwork stent would be the next step from a technological and medical point of view. Of particular interest is the careful study of microbleb formation and its effect on IOP.

Finally, the introduced approach could also be transferred to other stent designs and applications.

Acknowledgments

P. Jund and M. Bächtold are acknowledged for valuable discussions.

Appendix A. Calculation of Resistance R0

In the drawing below, the shaded rectangles are the unit cells (repeating blocks) of the stent. The resistance within a rectangle is also the resistance R0 between two successive outlet tubes along a stent column. The resistance of a rectangle does not change when it is moved, considering that the resistance of a mesh tube doubles (in red) when it is shared among two cells. The stent resistance may not depend on the choice of the unit cell. The resistance of each of the three highlighted rectangles is R0=32R.

Figure A1.

Figure A1

Various possible unit cells of the tubular hexagonal mesh are shown as shaded rectangles. The total resistance R0 in each unit cell is the same.

Appendix B. Aqueous Humor Production Rate and Uveoscleral Outflow

AH production rate is individual for each person and depends on several factors. It was found to be 2.4±0.6 μL/min (mean ± SD) over the daytime in the age group 20–83 years, although 2.63±0.63 μL/min was also reported [25,33]. The rate varies diurnally and is usually about 3.0 μL/min in the morning, 2.4 μL/min in the afternoon, and drops to 1.5 μL/min at night [25]. With increasing age, the rate decreases slightly, falling at approximately 3.2% per decade from the age of 10, with no gender differences observed [33]. However, IOP does not usually decrease with age-related decline in humor production because of the counteracting increase in outflow resistance of TM with increasing age [34]. AH production rate was reported to be insensitive to moderate IOP changes [25,33,35]. White individuals affected by POAG or OHT were found to have similar production rates (2.36±0.63 μL/min) compared to the healthy control group (2.19±0.47 μL/min), while in black subjects, the healthy control group had a lower rate (1.81±0.53 μL/min) than POAG/OHT affected patients (2.35±0.53 μL/min) [35]. POAG patients are the potential group for glaucoma surgery but the humor rate data from the aforementioned study was obtained from a rather limited number of participants (POAG/OHT: 66, Control: 15).

Uveoscleral outflow was found to be between 4% to 54% of total outflow [27,36]. One reason for the large variations are the measurement methods. Indirect methods estimate uveoscleral outflow using humor production rate, trabecular outflow resistance and pEV, where pEV is not precisely known and has a significant impact on the result. Indirect methods result then in larger uveoscleral outflow than direct methods. Direct measurements in the human eye suggest a value of less than 15% [27,36]. Age-related decrease in uveoscleral flow was observed. A value of 1.52 mL/min was reported in eyes aged 20–30 years compared with 1.10 mL/min in eyes older than 60 years [27]. Similar to the ocular AH production rate, uveoscleral outflow is relatively pressure-independent in the normal IOP range [27].

Appendix C. Step-by-Step Procedure for a Hexagonal Glaucoma Stent Design

Table A1.

The step-by-step procedure for personalized stent design.

Steps Input Input Output Equation
1 IOPBS measured before surgery, e.g., 25 mmHg IOPAS targeted after surgery, e.g., 14 mmHg Serial outflow resistance Rsa of stent and bleb array Rsa=IOPASIOPBSpEVQ˙Q˙UPIOPBSIOPAS
Equation (16), e.g., Q˙Q˙UP=2.1μLmin
2 Hemispherical bleb radius for COMSOL simulation, e.g., rb=30 μm Bleb spacing in array for COMSOL simulation, e.g.,
da=300 μm
Bleb array drainage resistance Ra Ra=pb/Q˙s
where pb is the pressure in the blebs from COMSOL simulation and Q˙s is the flow rate through the stent, e.g., Q˙s=1.7μLmin
Ra>4×104mmHgminμL·μmn·rbμm
Equation (13), where n is the number of outlets
3 Rsa (from step 1) Ra (from step 2) Stent flow resistance Rs Rs=RsaRa
4 Number of stent columns, e.g., nc=42 Number of stent rows, e.g., nr=20 Number of stent outlets and micro blebs n=nc·nr
5 Stent column resistance Rc=nc·Rs Fix lowest stent outlet resistance,
e.g., R1=R0/10
Stent flow resistance R0 connecting two outlet tubes R0=6nrRcR1nr3nr1=6nRsR1nr3nr1
Equation (5)
6 Hexagonal segment flow resistance R=23R0 Bleb spacing da Channel length L and cross section width D of hex. segment L=datan30° (geometry of hexagon)
D=28.4·ηLR14=42.7·ηLR014
Equations (1) and (2)
7 R0 (from step 5) Lowest stent outlet resistance
R1 (from step 5)
Flow resistance Rk of outlet tube in row number k Rk=12kk1R0+R1 Equation (4)
8 Length LK of straight outlet tube, e.g., 100 μm Row number k Cross section width of outlet tube Dk=28.4·ηLkRk14
Equation (3)

Appendix D. List of Parameters Used for Calculations

Table A2.

Governing parameters for calculations.

Parameter Value SI Units Description
ϱ 103 kgm3 Density of fluid, of AH
η 7×104 Pa·s Dynamic viscosity of liquid
K 5×1013 m2Pa·s Hydraulic conductivity in subconjunctival tissue [6]
κ=K·η 3.5×1016 m2 Fluid permeability in subconjunctival tissue, used in Equation (6)
Sp=ϱ·LpSAV 103 sm2 Used in Equation (6)
Lp 1010 mPa·s Hydraulic permeability of blood vessel wall [6]
SAV 104 1m Vessel wall area per tissue volume [6]
1C=ϱSpκη 7×104 m Characteristic drainage length, used in Equation (8)
Q˙ 2.5 μLmin Typical AH production rate
Q˙UP0.15·Q˙ 0.4 μLmin Constant outflow rate through uveoscleral pathway
pEV 11 mmHg Episcleral venous pressure, ranging from 9 to 12 mmHg [6]

Author Contributions

Conceptualization, T.G. and P.E.; modeling and simulations, T.G.; data analysis, writing and review, T.G., G.K., L.J. and P.E.; project administration, P.E. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

We thank the Swiss Innovation Agency, Innosuisse, for partially funding this work (Nr.: 53982.1 INNO-LS).

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Allison K., Patel D., Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020;12:e11686. doi: 10.7759/cureus.11686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zhang N., Wang J., Li Y., Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: A meta-analysis and systematic review. Sci. Rep. 2021;11:13762. doi: 10.1038/s41598-021-92971-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013. [DOI] [PubMed] [Google Scholar]
  • 4.Lee R.M.H., Bouremel Y., Eames I., Brocchini S., Khaw P.T. Translating Minimally Invasive Glaucoma Surgery Devices. Clin. Transl. Sci. 2020;13:14–25. doi: 10.1111/cts.12660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Do A.T., Parikh H., Panarelli J.F. Subconjunctival microinvasive glaucoma surgeries: An update on the Xen gel stent and the PreserFlo MicroShunt. Curr. Opin. Ophthalmol. 2020;31:132–138. doi: 10.1097/ICU.0000000000000643. [DOI] [PubMed] [Google Scholar]
  • 6.Gardiner B.S., Smith D.W., Coote M., Crowston J.G. Computational modeling of fluid flow and intra-ocular pressure following glaucoma surgery. PLoS ONE. 2010;5:e13178. doi: 10.1371/journal.pone.0013178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zada M., Pattamatta U., White A. Modulation of Fibroblasts in Conjunctival Wound Healing. Ophthalmology. 2018;125:179–192. doi: 10.1016/j.ophtha.2017.08.028. [DOI] [PubMed] [Google Scholar]
  • 8.Yamanaka O., Kitano-Izutani A., Tomoyose K., Reinach P.S. Pathobiology of wound healing after glaucoma filtration surgery. BMC Ophthalmol. 2015;15:19–27. doi: 10.1186/s12886-015-0134-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Andrew N.H., Akkach S., Casson R.J. A review of aqueous outflow resistance and its relevance to microinvasive glaucoma surgery. Surv. Ophthalmol. 2019;65:18–31. doi: 10.1016/j.survophthal.2019.08.002. [DOI] [PubMed] [Google Scholar]
  • 10.Fea A.M., Durr G.M., Marolo P., Malinverni L., Economou M.A., Ahmed I. Xen® gel stent: A comprehensive review on its use as a treatment option for refractory glaucoma. Clin. Ophthalmol. 2020;14:1805–1832. doi: 10.2147/OPTH.S178348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang J., Barton K. Minimally Invasive Glaucoma Surgery. Springer; Singapore: 2021. Overview of MIGS; pp. 1–10. [DOI] [Google Scholar]
  • 12.Lenzhofer M., Hohensinn M., Strohmaier C., Reitsamer H.A. Subconjunctival minimally invasive glaucoma surgery: Methods and clinical results. Ophthalmologe. 2018;115:381–387. doi: 10.1007/s00347-018-0669-1. [DOI] [PubMed] [Google Scholar]
  • 13.Green W., Lind J.T., Sheybani A. Review of the Xen Gel Stent and InnFocus MicroShunt. Curr. Opin. Ophthalmol. 2018;29:162–170. doi: 10.1097/ICU.0000000000000462. [DOI] [PubMed] [Google Scholar]
  • 14.Ishida K., Nakano Y., Ojino K., Shimazawa M., Otsuka T., Inagaki S., Kawase K., Hara H., Yamamoto T. Evaluation of Bleb Characteristics after Trabeculectomy and Glaucoma Implant Surgery in the Rabbit. Ophthalmic Res. 2020;64:68–76. doi: 10.1159/000509135. [DOI] [PubMed] [Google Scholar]
  • 15.Fea A.M., Spinetta R., Cannizzo P.M.L., Consolandi G., Lavia C., Aragno V., Germinetti F., Rolle T. Evaluation of Bleb Morphology and Reduction in IOP and Glaucoma Medication following Implantation of a Novel Gel Stent. J. Ophthalmol. 2017;2017:9364910. doi: 10.1155/2017/9364910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shobayashi K., Inoue T., Kawai M., Iwao K., Ohira S., Kojima S., Kuroda U., Nakashima K., Tanihara H. Postoperative changes in aqueous monocyte chemotactic protein-1 levels and bleb morphology after trabeculectomy vs. Ex-PRESS shunt surgery. PLoS ONE. 2015;10:e0139751. doi: 10.1371/journal.pone.0139751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kokubun T., Yamamoto K., Sato K., Akaishi T., Shimazaki A., Nakamura M., Shiga Y., Tsuda S., Omodaka K., Nakazawa T. The effectiveness of colchicine combined with mitomycin C to prolong bleb function in trabeculectomy in rabbits. PLoS ONE. 2019;14:e0213811. doi: 10.1371/journal.pone.0213811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Amoozgar B., Wei X., Lee J.H., Bloomer M., Zhao Z., Coh P., He F., Luan L., Xie C., Han Y. A novel flexible microfluidic meshwork to reduce fibrosis in glaucoma surgery. PLoS ONE. 2017;12:e0172556. doi: 10.1371/journal.pone.0172556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hinkle D.M., Zurakowski D., Ayyala R.S. A comparison of the polypropylene plate AhmedTM glaucoma valve to the silicone plate AhmedTM glaucoma flexible valve. Eur. J. Ophthalmol. 2007;17:696–701. doi: 10.1177/112067210701700502. [DOI] [PubMed] [Google Scholar]
  • 20.Gibson L.J., Ashby M.F. Cellular Solids: Structure and Properties. 2nd ed. Cambridge University Press; Cambridge, UK: 1997. [DOI] [Google Scholar]
  • 21.COMSOL Multiphysics 5.6. 2020. [(accessed on 16 June 2022)]. Available online: https://www.comsol.com/comsol-multiphysics.
  • 22.Kudsieh B., Fernández-Vigo J.I., Agujetas R., Montanero J.M., Ruiz-Moreno J.M., Fernández-Vigo J.Á., García-Feijóo J. Numerical model to predict and compare the hypotensive efficacy and safety of minimally invasive glaucoma surgery devices. PLoS ONE. 2020;15:e0239324. doi: 10.1371/journal.pone.0239324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sheybani A., Reitsamer H., Ahmed I.I.K. Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma. Investig. Ophthalmol. Vis. Sci. 2015;56:4789–4795. doi: 10.1167/iovs.15-16625. [DOI] [PubMed] [Google Scholar]
  • 24.Bruus H. Theoretical Microfluidics. Oxford University Press; Oxford, UK: 2008. [Google Scholar]
  • 25.Ethier C.R., Johnson M., Ruberti J. Ocular biomechanics and biotransport. Annu. Rev. Biomed. Eng. 2004;6:249–273. doi: 10.1146/annurev.bioeng.6.040803.140055. [DOI] [PubMed] [Google Scholar]
  • 26.Villamarin A., Roy S., Hasballa R., Vardoulis O., Reymond P., Stergiopulos N. 3D simulation of the aqueous flow in the human eye. Med. Eng. Phys. 2012;34:1462–1470. doi: 10.1016/j.medengphy.2012.02.007. [DOI] [PubMed] [Google Scholar]
  • 27.Alm A., Nilsson S.F.E. Uveoscleral outflow—A review. Exp. Eye Res. 2009;88:760–768. doi: 10.1016/j.exer.2008.12.012. [DOI] [PubMed] [Google Scholar]
  • 28.Szopos M., Cassani S., Guidoboni G., Prud’homme C., Sacco R., Siesky B., Harris A. Mathematical modeling of aqueous humor flow and intraocular pressure under uncertainty: Towards individualized glaucoma management. Model Artif. Intell. Ophthalmol. 2016;1:29–39. doi: 10.35119/maio.v1i2.24. [DOI] [Google Scholar]
  • 29.Jain R.K., Tong R.T., Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res. 2007;67:2729–2735. doi: 10.1158/0008-5472.CAN-06-4102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Jonušauskas L., Baravykas T., Andrijec D., Gadišauskas T., Purlys V. Stitchless support-free 3D printing of free-form micromechanical structures with feature size on-demand. Sci. Rep. 2019;9:17533. doi: 10.1038/s41598-019-54024-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Merkininkaitė G., Gailevičius D., Šakirzanovas S., Jonušauskas L. Polymers for Regenerative Medicine Structures Made via Multiphoton 3D Lithography. Int. J. Polym. Sci. 2019;2019:3403548. doi: 10.1155/2019/3403548. [DOI] [Google Scholar]
  • 32.Mačiulaitis J., Deveikyte M., Rekštyte S., Bratchikov M., Darinskas A., Šimbelyte A., Daunoras G., Laurinavičiene A., Laurinavičius A., Gudas R., et al. Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography. Biofabrication. 2015;7:015015. doi: 10.1088/1758-5090/7/1/015015. [DOI] [PubMed] [Google Scholar]
  • 33.Maus T.L., Brubaker R.F. Measurement of aqueous humor flow by fluorophotometry in the presence of a dilated pupil. IOVS. 1999;40:542–546. [PubMed] [Google Scholar]
  • 34.Gabelt B.T., Kaufman P.L. Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye Res. 2005;24:612–637. doi: 10.1016/j.preteyeres.2004.10.003. [DOI] [PubMed] [Google Scholar]
  • 35.Beltran-Agullo L., Alaghband P., Rashid S., Gosselin J., Obi A., Husain R., Lim K.S. Comparative human aqueous dynamics study between black and white subjects with glaucoma. Investig. Ophthalmol. Vis. Sci. 2011;52:9425–9430. doi: 10.1167/iovs.10-7130. [DOI] [PubMed] [Google Scholar]
  • 36.Nilsson S.F.E. The uveoscleral outflow routes. Eye. 1997;11:149–154. doi: 10.1038/eye.1997.43. [DOI] [PubMed] [Google Scholar]

Articles from Micromachines are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES